KTTA Berita Valas

Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development

Biotechnology company Pasithea Therapeutics Corp. (KTTA) announced Wednesday receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding clinical development plan for PAS-004.

RTTNews | 674 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.17349	GBPUSD	1.3447	AUDUSD	0.66033
USDJPY	147.306	USDCAD	1.39618	USDCHF	0.79608